

Clatterbridge Cancer Centre Performance in Delivering Research Q3 2014-15 (Apr-Dec 14)

Id	Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
41574	13/LO/1020	NCRN640 Celestial Cabozantinib vs. Placebo in Subjects with HCCA Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who have Received Prior Sorafenib	5	31/01/2017	Open	N/A	Trial still open and actively recruiting
41575	14/NW/0020	NCRN 2630 Bayer 16507 A three arm randomized,1 open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg, and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone	6	30/09/2023	Open	N/A	Trial still open and actively recruiting
41576	13/LO/1581	NCRN - 2643 DNIB0600A in patients with Platinum-Resistant Ovarian Cancer	4	01/01/2016	Open	N/A	Trial still open and actively recruiting
41577	14/LO/0135	BAYER 15396 Radium223A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-na?ve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)	6	30/07/2021	Open	N/A	Trial still open and actively recruiting
41578	13/SC/0478	NCRN 567 COLUMBUS - A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma	3	21/08/2017	Open	N/A	Trial still open and actively recruiting
41579	14/LO/0022	Renal Cell WO29074 NCRN 2511 A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA	4	07/01/2017	Suspended	N/A	
41580	13/LO/1050	EISAI HCC - Protocol E7080-G000-304 (Unresectable Hepatocellular Carcinoma)A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma	6	01/06/2016	Open	N/A	Trial still open and actively recruiting
41581	14/SW/0091	NCRN - 2974 VESTA: NSCLC M11089 A Phase 3 Veliparib plus Chemotherapy Study in Adv/Met squamous NSCLC	8	31/03/2016	Open	N/A	Trial still open and actively recruiting
41582	14/SC/0199	CHECKMATE 141 - An open label, randomised phase 3 clinical trial of Nivolumab vs therapy of investigator?s choice in recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN)	4	31/12/2015	Open	N/A	Trial still open and actively recruiting
41583	14/LO/1042	GO29293 - MPDL3280A in metastatic bladder cancer	5	01/05/2018	Open	N/A	Trial still open and actively recruiting
41584	14/NW/1036	SHIONOGI BLADDER 1408P192 A multicenter, open-label, phase 2 study of S-588410 as maintenance monotherapy after first-line platinumcontaining chemotherapy in patients with advanced and/or metastatic bladder cancer	4	30/09/2017	Open	N/A	Trial still open and actively recruiting
41585	13/EM/0230	NCRN636 - VS-6063 in mesothelioma - A phase II randomised, double blind, placebo-controlled, multicentre study of VS-6063 in subjects with malignant pleural mesothelioma	8	31/12/2016	Open	N/A	Trial still open and actively recruiting
41593	14/LO/1052	A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral GnRH Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)	10	14/09/2015	Open	N/A	Trial still open and actively recruiting

41594	14/NW/0350	A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM) (CheckMate 143: CHECKpoint pathway and nivolumab clinical Trial Evaluation 143)	3	31/01/2018	Open	N/A	Trial still open and actively recruiting
41595	14/NE/1079	A randomized, double-blind, placebo-controlled study to evaluate the Efficacy of two different dose levels of orvepitant (10 and 30mg) compared with placebo on EGFRi-induced intense pruritus in oncology subjects	5	24/02/2015	Open	N/A	Trial still open and actively recruiting
41596	14/LO/1151	A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone	15	30/08/2015	Open	N/A	Trial still open and actively recruiting
41597	14/SC/1167	PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTI-CENTER, TWO-PART STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH ERLOTINIB IN EGFR WILD-TYPE SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON AT LEAST ONE PRIOR SYSTEMIC THERAPY U31287-A-U301	6	03/08/2015	Open	N/A	Trial still open and actively recruiting
41598	14/LO/1672	Polo Pancreatic 217674	2	22/11/2017	Open	N/A	Trial still open and actively recruiting